{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T08:56:19Z","timestamp":1769331379174,"version":"3.49.0"},"reference-count":31,"publisher":"China Science Publishing & Media Ltd.","content-domain":{"domain":["engine.scichina.com"],"crossmark-restriction":false},"short-container-title":["ABBS"],"published-print":{"date-parts":[[2023,11,1]]},"DOI":"10.3724\/abbs.2023260","type":"journal-article","created":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:53:13Z","timestamp":1701046393000},"update-policy":"https:\/\/doi.org\/10.1360\/scp-crossmark-policy-page","source":"Crossref","is-referenced-by-count":3,"title":["Dihydrocelastrol induces antitumor activity and enhances the sensitivity of bortezomib in resistant multiple myeloma by inhibiting STAT3-dependent PSMB5 regulation"],"prefix":"10.3724","author":[{"given":"Shuhan","family":"Jin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuejie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuaikang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongliang","family":"Song","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huabin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cheng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yumeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gege","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2026","published-online":{"date-parts":[[2023,11,27]]},"reference":[{"key":"CITATION1","doi-asserted-by":"crossref","unstructured":"Firth J. Haematology: multiple myeloma.                                                       Clini Med                          (London, England) 2019, 19: 58\u201360.","DOI":"10.7861\/clinmedicine.19-1-58"},{"key":"CITATION2","doi-asserted-by":"crossref","unstructured":"Twombly R. First proteasome inhibitor approved for multiple myeloma.                                                       J Natl Cancer Inst                          2003, 95: 845\u2013845.","DOI":"10.1093\/jnci\/95.12.845"},{"key":"CITATION3","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","volume":"12","author":"Dimopoulos MA","year":"2015","unstructured":"Dimopoulos MA, Richardson PG, Moreau P, Anderson KC. Current treatment landscape for relapsed and\/or refractory multiple myeloma. Nat Rev Clin Oncol, 2015, 12: 42-54.","journal-title":"Nat Rev Clin Oncol"},{"key":"CITATION4","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","volume":"95","author":"Rajkumar SV","year":"2020","unstructured":"Rajkumar SV. Multiple myeloma: 2020 update on diagnosis, risk\u2010stratification and management. Am J Hematol, 2020, 95: 548-567.","journal-title":"Am J Hematol"},{"key":"CITATION5","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev.med.57.042905.122625","volume":"57","author":"Richardson PG","year":"2006","unstructured":"Richardson PG, Mitsiades C, Hideshima T, Anderson KC. Bortezomib: proteasome inhibition as an effective anticancer therapy. Annu Rev Med, 2006, 57: 33-47.","journal-title":"Annu Rev Med"},{"key":"CITATION6","doi-asserted-by":"crossref","unstructured":"Kisselev AF. Site-specific proteasome inhibitors.                                                       Biomolecules                          2021, 12: 54.","DOI":"10.3390\/biom12010054"},{"key":"CITATION7","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1007\/s10555-017-9707-8","volume":"36","author":"Gandolfi S","year":"2017","unstructured":"Gandolfi S, Laubach JP, Hideshima T, Chauhan D, Anderson KC, Richardson PG. The proteasome and proteasome inhibitors in multiple myeloma. Cancer Metastasis Rev, 2017, 36: 561-584.","journal-title":"Cancer Metastasis Rev"},{"key":"CITATION8","doi-asserted-by":"publisher","first-page":"5661","DOI":"10.1182\/blood-2012-03-414359","volume":"119","author":"Vij R","year":"2012","unstructured":"Vij R, Wang M, Kaufman JL, Lonial S, Jakubowiak AJ, Stewart AK, Kukreti V. An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and\/or refractory multiple myeloma. Blood, 2012, 119: 5661-5670.","journal-title":"Blood"},{"key":"CITATION9","doi-asserted-by":"publisher","first-page":"4758","DOI":"10.1158\/0008-5472.CAN-05-4529","volume":"66","author":"Yang H","year":"2006","unstructured":"Yang H, Chen D, Cui QC, Yuan X, Dou QP. Celastrol, a triterpene extracted from the Chinese \u201cthunder of god vine,\u201d is a potent proteasome inhibitor and suppresses human prostate cancer growth in nude mice. Cancer Res, 2006, 66: 4758-4765.","journal-title":"Cancer Res"},{"key":"CITATION10","doi-asserted-by":"crossref","unstructured":"Yan F, Wu ZH, Li ZH, Liu L. Celastrol inhibits migration and invasion of triple-negative breast cancer cells by suppressing interleukin-6 via downregulating nuclear factor-kappa b (NF-kappa B).                                                       Med Sci Monitor                          2020, 26: 9.","DOI":"10.12659\/MSM.922814"},{"key":"CITATION11","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1271\/bbb.67.1883","volume":"67","author":"Nagase M","year":"2003","unstructured":"Nagase M, Oto J, Sugiyama S, Yube K, Takaishi Y, Sakato N. Apoptosis induction in HL-60 cells and inhibition of topoisomerase II by triterpene celastrol. Biosci Biotechnol Biochem, 2003, 67: 1883-1887.","journal-title":"Biosci Biotechnol Biochem"},{"key":"CITATION12","doi-asserted-by":"crossref","unstructured":"Li HY, Zhang J, Sun LL, Li BH, Gao HL, Xie T, Zhang N,                          et al. Celastrol induces apoptosis and autophagy via the ROS\/JNK signaling pathway in human osteosarcoma cells: an                          in vitro and                          in vivo study.                                                       Cell Death Dis                          2015, 6: 14.","DOI":"10.1038\/cddis.2014.543"},{"key":"CITATION13","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1111\/j.1476-5381.2011.01449.x","volume":"164","author":"Kannaiyan R","year":"2011","unstructured":"Kannaiyan R, Hay HS, Rajendran P, Li F, Shanmugam MK, Vali S, Abbasi T. Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-\u03baB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol, 2011, 164: 1506-1521.","journal-title":"Br J Pharmacol"},{"key":"CITATION14","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/abbs\/gmx021","volume":"49","author":"Hu L","year":"2017","unstructured":"Hu L, Wu H, Li B, Song D, Yang G, Chen G, Xie B. Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1\/2 and IL-6\/STAT3 pathways                          in vitro and                          in vivo. Acta Biochim Biophys Sin, 2017, 49: 420-427.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION15","doi-asserted-by":"crossref","unstructured":"Xie Y, Li B, Bu W, Gao L, Zhang Y, Lan X, Hou J,                          et al. Dihydrocelastrol exerts potent antitumor activity in mantle cell lymphoma cells via dual inhibition of mTORC1 and mTORC2.                                                       Int J Oncol                          2018, 53: 823\u2013834.","DOI":"10.3892\/ijo.2018.4438"},{"key":"CITATION16","doi-asserted-by":"crossref","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method.                                                       Cancer Res                          2010, 70: 440\u2013446.","DOI":"10.1158\/0008-5472.CAN-09-1947"},{"key":"CITATION17","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nrc.2016.138","volume":"17","author":"Otto T","year":"2017","unstructured":"Otto T, Sicinski P. Cell cycle proteins as promising targets in cancer therapy. Nat Rev Cancer, 2017, 17: 93-115.","journal-title":"Nat Rev Cancer"},{"key":"CITATION18","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1124\/pr.58.3.10","volume":"58","author":"Chou TC","year":"2006","unstructured":"Chou TC. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev, 2006, 58: 621-681.","journal-title":"Pharmacol Rev"},{"key":"CITATION19","doi-asserted-by":"crossref","unstructured":"Chou TC. The combination index (CI\u202f                             Synergy                          2018, 7: 49\u201350.","DOI":"10.1016\/j.synres.2018.04.001"},{"key":"CITATION20","doi-asserted-by":"publisher","first-page":"1278","DOI":"10.1016\/j.exphem.2008.04.013","volume":"36","author":"Lue S","year":"2008","unstructured":"Lue S, Chen Z, Yang J, Chen L, Gong S, Zhou H, Guo L. Overexpression of the PSMB5 gene contributes to bortezomib resistance in T-lymphoblastic lymphoma\/leukemia cells derived from Jurkat line. Exp Hematol, 2008, 36: 1278-1284.","journal-title":"Exp Hematol"},{"key":"CITATION21","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","volume":"112","author":"Oerlemans R","year":"2008","unstructured":"Oerlemans R, Franke NE, Assaraf YG, Cloos J, van Zantwijk I, Berkers CR, Scheffer GL. Molecular basis of bortezomib resistance: proteasome subunit \u03b25 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood, 2008, 112: 2489-2499.","journal-title":"Blood"},{"key":"CITATION22","doi-asserted-by":"publisher","first-page":"12612","DOI":"10.1074\/jbc.M113.542829","volume":"289","author":"Vangala JR","year":"2014","unstructured":"Vangala JR, Dudem S, Jain N, Kalivendi SV. Regulation of PSMB5 protein and \u03b2 subunits of mammalian proteasome by constitutively activated signal transducer and activator of transcription 3 (STAT3). J Biol Chem, 2014, 289: 12612-12622.","journal-title":"J Biol Chem"},{"key":"CITATION23","doi-asserted-by":"publisher","first-page":"517","DOI":"10.2174\/1568009614666140804154511","volume":"14","author":"Dou Q","year":"2014","unstructured":"Dou Q, Zonder J. Overview of proteasome inhibitor-based Anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of Ubiquitin-Proteasome system. Curr Cancer Drug Targets, 2014, 14: 517-536.","journal-title":"Curr Cancer Drug Targets"},{"key":"CITATION24","doi-asserted-by":"crossref","unstructured":"Shi YG. Mechanisms of caspase activation and inhibition during apoptosis.                                                       Mol Cell                          2002, 9: 459-470.","DOI":"10.1016\/S1097-2765(02)00482-3"},{"key":"CITATION25","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/abbs\/gmab042","volume":"53","author":"Ma R","year":"2021","unstructured":"Ma R, Yu D, Peng Y, Yi H, Wang Y, Cheng T, Shi B. Resveratrol induces AMPK and mTOR signaling inhibition-mediated autophagy and apoptosis in multiple myeloma cells. Acta Biochim Biophys Sin, 2021, 53: 775-783.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION26","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nrm2312","volume":"9","author":"Taylor RC","year":"2008","unstructured":"Taylor RC, Cullen SP, Martin SJ. Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol, 2008, 9: 231-241.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"CITATION27","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/j.tibs.2018.12.007","volume":"44","author":"Icard P","year":"2019","unstructured":"Icard P, Fournel L, Wu Z, Alifano M, Lincet H. Interconnection between metabolism and cell cycle in cancer. Trends Biochem Sci, 2019, 44: 490-501.","journal-title":"Trends Biochem Sci"},{"key":"CITATION28","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1093\/abbs\/gmab128","volume":"53","author":"Wang H","year":"2021","unstructured":"Wang H, Yu D, Zhang H, Ma R, Wu H, Zhai H, Wang H. Quercetin inhibits the proliferation of multiple myeloma cells by upregulating PTPRR expression. Acta Biochim Biophys Sin, 2021, 53: 1505-1515.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION29","doi-asserted-by":"crossref","unstructured":"Papadas A, Asimakopoulos F. Mechanisms of Resistance in Multiple Myeloma.                                                       Handb Exp Pharmacol                          2018, 249: 251\u2013288.","DOI":"10.1007\/164_2017_10"},{"key":"CITATION30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1093\/abbs\/gmab031","volume":"53","author":"Hu K","year":"2021","unstructured":"Hu K, Li B, Ma R, Yi H, Xu Z, Peng Y, Yu D. Anti-DLBCL efficacy of DCZ0825 and : involvement of the PI3K\u2012AKT\u2012mTOR\/JNK pathway. Acta Biochim Biophys Sin, 2021, 53: 575-583.","journal-title":"Acta Biochim Biophys Sin"},{"key":"CITATION31","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5301\/ijbm.5000283","volume":"33","author":"Wei W","year":"2018","unstructured":"Wei W, Zou Y, Jiang Q, Zhou Z, Ding H, Yan L, Yang S. PSMB5 is associated with proliferation and drug resistance in triple-negative breast cancer. Int J Biol Markers, 2018, 33: 102-108.","journal-title":"Int J Biol Markers"}],"container-title":["Acta Biochimica et Biophysica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/6371163710274B1AA9A5A8F17D39D243","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2023260","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/engine.scichina.com\/doi\/pdf\/6371163710274B1AA9A5A8F17D39D243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,27]],"date-time":"2023-11-27T00:53:20Z","timestamp":1701046400000},"score":1,"resource":{"primary":{"URL":"https:\/\/engine.scichina.com\/doi\/10.3724\/abbs.2023260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,1]]},"references-count":31,"URL":"https:\/\/doi.org\/10.3724\/abbs.2023260","relation":{},"ISSN":["1672-9145"],"issn-type":[{"value":"1672-9145","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11,1]]}}}